Old Web
English
Sign In
Acemap
>
Paper
>
PATH-21. ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
PATH-21. ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
2018
Thomas Urup
Linn Gillberg
Signe Regner Michaelsen
Ib Jarle Christensen
Helle Broholm
Ulrik Lassen
Kirsten Groenbaek
Hans Skovgaard Poulsen
Keywords:
Glioblastoma
Immunology
Bevacizumab
Gene silencing
Medicine
angiotensinogen gene
Cancer research
CCAAT/enhancer binding protein alpha
Gene expression
recurrent glioblastoma
Chemotherapy regimen
DNA methylation
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]